On Monday, UBS has adjusted its stock price target for AtriCure Inc. (NASDAQ:ATRC), a medical device company, to $35.00 from the previous $58.00. Despite this reduction, the firm retains a Buy rating on the company's stock.
AtriCure's shares have experienced a notable decline, falling approximately 35% year-to-date and dropping over 60% from their 52-week high. This decrease is attributed to concerns about a potential slow down or decrease in growth within its AtriClip business, which accounted for about 40% of the company's sales in 2023.
The AtriClip business has been a significant contributor to AtriCure's sales, adding just over 3 percentage points to the sales compound annual growth rate (CAGR) from 2018 to 2023, within a total CAGR of 14.6%.
The UBS analyst acknowledges the current market challenges AtriCure faces, including ongoing competitive trials and considerable market uncertainty, which are expected to prevent any significant near-to-medium term revaluation of AtriCure's shares.
UBS's revised valuation approach takes into account the broader devaluation across the small to mid-cap (SMID-cap) market segment, which has been influenced by competitive pressures and market disruptions. The firm's reverse discounted cash flow (DCF) analysis, based on AtriCure's current share price, suggests an 8% revenue growth over a 10-year period, which is below UBS's estimated 11% 10-year CAGR for the company.
Despite lowering the price target, UBS reaffirms its Buy rating on AtriCure, citing sustainable sales growth potential backed by key opinion leader (KOL) checks and confidence in the company's ability to improve its financial leverage moving forward. The firm's stance remains positive on AtriCure's prospects, even as it adjusts its expectations in light of recent market conditions.
In other recent news, AtriCure Inc. has reported a robust Q1 2024 performance, with revenue reaching $108.9 million, marking a 16.5% year-over-year increase. This figure surpassed both Canaccord Genuity's and the Street's expectations.
Despite a slight underperformance in its adjusted EBITDA, which was reported at $2.8 million, AtriCure reaffirmed its full-year 2024 guidance, projecting revenues between $459 million and $466 million, alongside an adjusted EBITDA ranging from $26 million to $29 million.
Despite the strong performance, AtriCure's shares target was reduced by Canaccord Genuity, Needham, and BTIG, maintaining a Buy rating on the stock. AtriCure's Minimally Invasive Ablation business, particularly the EPi-Sense product line, was highlighted for its strong performance. However, the Appendage Management segment underperformed, especially in the U.S. market.
These are recent developments, and the market reaction to the competitive dynamics and the segment's performance has led Canaccord Genuity to believe it has created a buying opportunity for AtriCure's shares. The firm's decision to lower the price target is based on a reduction in comparable group multiples, not a change in the company's fundamental outlook.
InvestingPro Insights
In light of UBS's recent adjustment of AtriCure Inc.'s price target, it's valuable to consider additional insights provided by InvestingPro. The company's market capitalization stands at $1.08 billion, reflecting investor valuation.
Despite the challenges highlighted, AtriCure has demonstrated robust revenue growth in the last twelve months as of Q1 2024, with an increase of 18.7%, and even a higher quarterly growth rate of 16.43%. This underscores the company's ability to expand its sales amidst market uncertainties.
On the profitability front, analysts from InvestingPro have flagged concerns, noting that AtriCure is not expected to be profitable this year and has not been profitable over the last twelve months. This aligns with UBS's cautious stance on the near-to-medium term revaluation of AtriCure's shares.
Moreover, the company's P/E ratio stands at -27.95, reflecting market skepticism about its earnings potential in the near future. Still, on a positive note, AtriCure's liquid assets exceed its short-term obligations, which could provide some financial flexibility in navigating current market challenges.
For those interested in deeper analysis and additional InvestingPro Tips, such as the company's moderate level of debt and absence of dividend payments to shareholders, AtriCure's profile on InvestingPro offers further details. Subscribers can use the coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription. There are 6 additional InvestingPro Tips available for AtriCure, providing a comprehensive outlook for informed investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.